Haduvio (oral nalbuphine ER)
Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
Key Facts
About Trevi Therapeutics
Trevi Therapeutics is dedicated to addressing the debilitating burden of chronic cough through the development of its lead candidate, Haduvio. The company's novel KAMA mechanism targets the cough reflex arc both centrally and peripherally, a differentiated approach in a therapeutic area with high unmet need. With positive Phase 2 data in hand for IPF chronic cough and refractory chronic cough, Trevi is advancing its late-stage clinical programs. The company is a publicly traded entity (NASDAQ: TRVI) headquartered in New Haven, Connecticut.
View full company profileAbout Trevi Therapeutics
Trevi Therapeutics is dedicated to addressing the debilitating burden of chronic cough through the development of its lead candidate, Haduvio. The company's novel KAMA mechanism targets the cough reflex arc both centrally and peripherally, a differentiated approach in a therapeutic area with high unmet need. With positive Phase 2 data in hand for IPF chronic cough and refractory chronic cough, Trevi is advancing its late-stage clinical programs. The company is a publicly traded entity (NASDAQ: TRVI) headquartered in New Haven, Connecticut.
View full company profileAbout Trevi Therapeutics
Trevi Therapeutics is dedicated to addressing the debilitating burden of chronic cough through the development of its lead candidate, Haduvio. The company's novel KAMA mechanism targets the cough reflex arc both centrally and peripherally, a differentiated approach in a therapeutic area with high unmet need. With positive Phase 2 data in hand for IPF chronic cough and refractory chronic cough, Trevi is advancing its late-stage clinical programs. The company is a publicly traded entity (NASDAQ: TRVI) headquartered in New Haven, Connecticut.
View full company profile